ClinicalTrials.gg
CompletedNCT01991184Updated Jun 21, 2022

A Study of GDC-0853 in Patients With Resistant B-Cell Lymphoma or Chronic Lymphocytic Leukemia.

A Phase 1 interventional study of GDC-0853 in Lymphocytic Leukemia, Chronic, Diffuse Large B-Cell Lymphoma, sponsored by Genentech, Inc.. Completed at 10 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2022-06-21.

Sponsored by Genentech, Inc. (part of Hoffmann-La Roche) · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
24
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 64 studies in Leukemia, Lymphoid with a site in United States — 8 open to participants now, 17 under way, 1 of them phase 3. Leukemia, Lymphoid · United States.

Enrollment
37th of 58
24 · median 31
Started
2013
with 1 other
Phase 1
21 of 64
1 open now
Registered
34th of 64
by date

Among the 64 studies in Leukemia, Lymphoid with a site in United States, this one is the 37th largest by enrollment of the 58 interventional ones that give a count, is one of 2 that started in 2013, is one of 21 in phase 1, and was the 34th registered.

Leukemia, Lymphoid

92 studies on the registry are indexed under Leukemia, Lymphoid; 14 are open to participants now.

Browse Leukemia, Lymphoid studies →

Open to participants now

8 of the 64 studies in Leukemia, Lymphoid with a site in United States are open now. Recruiting first, the newest first:

3 more — sign in →

All 8 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 12 Leukemia, Lymphoid studies recruiting now, 6 (50%) set no upper age limit and 6 (50%) stop at 75 or younger; 6 take children under 18; none take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 64 studies in Leukemia, Lymphoid with a site in United States, or all of them as a file.
02

Study summary

This open-label, Phase I study will evaluate the safety, tolerability, and pharmacokinetics of increasing doses of GDC-0853 in patients with relapsed or refractory B-cell non-Hodgkin's lymphoma or chronic lymphocytic leukemia. In a dose-expansion part, GDC-0853 will be assessed in subsets of patients.

03

Conditions studied

  • Lymphocytic Leukemia, Chronic, Diffuse Large B-Cell Lymphoma
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age >/= 18 years
  • score of 0-1
  • One of the following -documented hematologic for which no effective standard therapy exists: indolent non Hodgkin's lymphoma (NHL), follicular lymphoma (FL), diffuse large B-cell lymphoma (DLBCL), mantle cell lymphoma (MCL), or chronic lymphocytic leukemia (CLL)
  • At least one site of disease that, as seen on CT scan, is > 1.5 cm in the greatest transverse diameter or > 1.0 cm in short axis diameter (except for patients with CLL)
  • An available tumor specimen
  • Adequate hematologic and organ function
  • For female patients of and male patients with partners of childbearing potential, use of effective (s) as defined by protocol for the duration of the study

Exclusion criteria

Exclusion Criteria:

  • \< 12 weeks
  • \< 3 weeks since the last anti-tumor therapy, including chemotherapy, biologic, experimental, hormonal or radiotherapy (with the exception of leuprolide or similar medications for prostate cancer)
  • Recent major surgical procedure or traumatic injury, or unhealed incisions or wounds
  • Active infection requiring IV antibiotics
  • history of liver disease, including viral or other hepatitis, current alcohol abuse, or cirrhosis.
  • Primary CNS or untreated/active (progressing or requiring anticonvulsants or for symptomatic control)
  • History of other malignancy within 5 years prior to screening, except for appropriately treated carcinoma in situ of the cervix, non-melanoma skin cancer, Stage I uterine cancer, or other cancers with a similar outcome
  • Cardiovascular dysfunction, including ventricular dysrhythmias or risk factors for ventricular dysrhythmias
  • Pregnancy, or lactation
  • Any other diseases that contraindicates the use of an drug or that may affect the interpretation of the results or render the patient at high risk from treatment complications
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
24 participants (actual)

Study arms

  • Experimental
    Dose-escalation

    Drug: GDC-0853

Interventions

  • Multiple escalating doses

    Also known as: Fenebrutinib

06

What researchers measure

Primary outcomes

  1. Safety: Incidence of dose-limiting toxicities (DLTs) of GDC-0853

    Time frame: Approximately 1 year

  2. Safety: Maximum tolerated dose (MTD) of GDC-0853

    Time frame: Approximately 1 year

Secondary outcomes

  1. Safety: Incidence of adverse events

    Time frame: Approximately 2 years

  2. Pharmacokinetics: Area under the concentration-time curve (AUC) of GDC-0853

    Time frame: 35 days

  3. Pharmacokinetics: Maximum concentration (Cmax) of GDC-0853

    Time frame: 35 days

  4. Objective response to GDC-0853

    Time frame: Approximately 2 years

  5. Progression-free survival

    Time frame: Approximately 2 years

07

Study locations

10 sites
  • Stanford Cancer Center
    Stanford, California 94305-5820, United States
  • Washington University School of Medicine
    Saint Louis, Missouri 63110, United States
  • The Ohio State University Wexner Medical Center
    Columbus, Ohio 43212, United States
  • Willamette Valley Cancer Ctr - 520 Country Club
    Eugene, Oregon 97401-8122, United States
  • Oregon Health Sciences Uni
    Portland, Oregon 97239, United States
  • Sarah Cannon Cancer Center - Tennessee Oncology, Pllc
    Nashville, Tennessee 37203, United States
  • Seattle Cancer Care Alliance
    Seattle, Washington 98109, United States
  • Princess Alexandra Hospital Woolloongabba; Clinical Hematology and Medical Oncology
    Woolloongabba, Queensland 4102, Australia
  • Peter MacCallum Cancer Centre; Department of Haematology
    Melbourne, Victoria 3002, Australia
  • Linear Clinical Research Limited
    Nedlands, Western Australia 6009, Australia
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Dec 2013 to primary completion in Mar 2022, 98 months.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 18, 2013
First posted
Nov 25, 2013
StartActual
Dec 16, 2013
Primary completionActual
Mar 8, 2022
CompletionActual
Mar 8, 2022
Last update
Jun 21, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 21, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT01991184
Lead sponsor
Genentech, Inc.
Responsible party
Sponsor
First posted
Nov 25, 2013
Start date
Dec 16, 2013
Primary completion
Mar 8, 2022
Completion
Mar 8, 2022
Last update
Jun 21, 2022

Study contacts

Clinical Trials
study director · Genentech, Inc.
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Fenebrutinib

Start the discussion